Low dose versus conventional dose of intravitreal bevacizumab injection for retinopathy of prematurity: a case series with paired-eye comparison

Jinu Han, Seong Eun Kim, Sung Chul Lee, Christopher Seungkyu Lee

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Purpose: To compare the clinical outcomes of intravitreal bevacizumab (IVB) injection, with different dosing (0.25 mg/0.01 ml versus 0.625 mg/0.025 ml) in each eye of the same patient with retinopathy of prematurity (ROP). Methods: Intravitreal bevacizumab (IVB) was injected into eight patients with stage 3+ in zone I or posterior zone II ROP (16 eyes). Bevacizumab, with different dosing (0.25 mg/0.01 ml and 0.625 mg/0.025 ml), was injected into the vitreous cavity of each eye. Results: Among the 16 eyes treated with IVB, six eyes had zone I ROP and 10 eyes had zone II ROP. The mean birthweight was 800 ± 139 g (range, 533–955 g), and the mean gestational age was 25.9 ± 1.2 gestational weeks (range, 24.4–28.7 weeks). The postmenstrual age at initial treatment was 37.2 gestational weeks (range, 33.7–41 weeks). The mean follow-up was 312 ± 50 days (median, 305 days; range, 238–376 days). All eyes showed regression of plus sign after IVB injection within 1 week and revascularization to the ora serrata at the time of final visit. There was no difference in the time of anatomical achievement between the eyes with different doses. None of the patients received any additional IVB injection or laser photocoagulation. After the regression of ROP, tractional retinal detachment and macular ectopia were not observed in any patients during follow-up. Conclusions: There was no difference in the short-term clinical outcomes of stage 3+ ROP in zone I or II between the eyes with low dose and conventional dose of IVB.

Original languageEnglish
Pages (from-to)e475-e478
JournalActa Ophthalmologica
Volume96
Issue number4
DOIs
Publication statusPublished - 2018 Jun

Fingerprint

Matched-Pair Analysis
Retinopathy of Prematurity
Intravitreal Injections
Bevacizumab
Light Coagulation
Retinal Detachment
Gestational Age
Lasers

All Science Journal Classification (ASJC) codes

  • Ophthalmology

Cite this

@article{6afcc2ac39724acbb6bc3cb14c3e1e50,
title = "Low dose versus conventional dose of intravitreal bevacizumab injection for retinopathy of prematurity: a case series with paired-eye comparison",
abstract = "Purpose: To compare the clinical outcomes of intravitreal bevacizumab (IVB) injection, with different dosing (0.25 mg/0.01 ml versus 0.625 mg/0.025 ml) in each eye of the same patient with retinopathy of prematurity (ROP). Methods: Intravitreal bevacizumab (IVB) was injected into eight patients with stage 3+ in zone I or posterior zone II ROP (16 eyes). Bevacizumab, with different dosing (0.25 mg/0.01 ml and 0.625 mg/0.025 ml), was injected into the vitreous cavity of each eye. Results: Among the 16 eyes treated with IVB, six eyes had zone I ROP and 10 eyes had zone II ROP. The mean birthweight was 800 ± 139 g (range, 533–955 g), and the mean gestational age was 25.9 ± 1.2 gestational weeks (range, 24.4–28.7 weeks). The postmenstrual age at initial treatment was 37.2 gestational weeks (range, 33.7–41 weeks). The mean follow-up was 312 ± 50 days (median, 305 days; range, 238–376 days). All eyes showed regression of plus sign after IVB injection within 1 week and revascularization to the ora serrata at the time of final visit. There was no difference in the time of anatomical achievement between the eyes with different doses. None of the patients received any additional IVB injection or laser photocoagulation. After the regression of ROP, tractional retinal detachment and macular ectopia were not observed in any patients during follow-up. Conclusions: There was no difference in the short-term clinical outcomes of stage 3+ ROP in zone I or II between the eyes with low dose and conventional dose of IVB.",
author = "Jinu Han and Kim, {Seong Eun} and Lee, {Sung Chul} and Lee, {Christopher Seungkyu}",
year = "2018",
month = "6",
doi = "10.1111/aos.13004",
language = "English",
volume = "96",
pages = "e475--e478",
journal = "Acta Ophthalmologica",
issn = "1755-375X",
publisher = "Wiley-Blackwell",
number = "4",

}

Low dose versus conventional dose of intravitreal bevacizumab injection for retinopathy of prematurity : a case series with paired-eye comparison. / Han, Jinu; Kim, Seong Eun; Lee, Sung Chul; Lee, Christopher Seungkyu.

In: Acta Ophthalmologica, Vol. 96, No. 4, 06.2018, p. e475-e478.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Low dose versus conventional dose of intravitreal bevacizumab injection for retinopathy of prematurity

T2 - a case series with paired-eye comparison

AU - Han, Jinu

AU - Kim, Seong Eun

AU - Lee, Sung Chul

AU - Lee, Christopher Seungkyu

PY - 2018/6

Y1 - 2018/6

N2 - Purpose: To compare the clinical outcomes of intravitreal bevacizumab (IVB) injection, with different dosing (0.25 mg/0.01 ml versus 0.625 mg/0.025 ml) in each eye of the same patient with retinopathy of prematurity (ROP). Methods: Intravitreal bevacizumab (IVB) was injected into eight patients with stage 3+ in zone I or posterior zone II ROP (16 eyes). Bevacizumab, with different dosing (0.25 mg/0.01 ml and 0.625 mg/0.025 ml), was injected into the vitreous cavity of each eye. Results: Among the 16 eyes treated with IVB, six eyes had zone I ROP and 10 eyes had zone II ROP. The mean birthweight was 800 ± 139 g (range, 533–955 g), and the mean gestational age was 25.9 ± 1.2 gestational weeks (range, 24.4–28.7 weeks). The postmenstrual age at initial treatment was 37.2 gestational weeks (range, 33.7–41 weeks). The mean follow-up was 312 ± 50 days (median, 305 days; range, 238–376 days). All eyes showed regression of plus sign after IVB injection within 1 week and revascularization to the ora serrata at the time of final visit. There was no difference in the time of anatomical achievement between the eyes with different doses. None of the patients received any additional IVB injection or laser photocoagulation. After the regression of ROP, tractional retinal detachment and macular ectopia were not observed in any patients during follow-up. Conclusions: There was no difference in the short-term clinical outcomes of stage 3+ ROP in zone I or II between the eyes with low dose and conventional dose of IVB.

AB - Purpose: To compare the clinical outcomes of intravitreal bevacizumab (IVB) injection, with different dosing (0.25 mg/0.01 ml versus 0.625 mg/0.025 ml) in each eye of the same patient with retinopathy of prematurity (ROP). Methods: Intravitreal bevacizumab (IVB) was injected into eight patients with stage 3+ in zone I or posterior zone II ROP (16 eyes). Bevacizumab, with different dosing (0.25 mg/0.01 ml and 0.625 mg/0.025 ml), was injected into the vitreous cavity of each eye. Results: Among the 16 eyes treated with IVB, six eyes had zone I ROP and 10 eyes had zone II ROP. The mean birthweight was 800 ± 139 g (range, 533–955 g), and the mean gestational age was 25.9 ± 1.2 gestational weeks (range, 24.4–28.7 weeks). The postmenstrual age at initial treatment was 37.2 gestational weeks (range, 33.7–41 weeks). The mean follow-up was 312 ± 50 days (median, 305 days; range, 238–376 days). All eyes showed regression of plus sign after IVB injection within 1 week and revascularization to the ora serrata at the time of final visit. There was no difference in the time of anatomical achievement between the eyes with different doses. None of the patients received any additional IVB injection or laser photocoagulation. After the regression of ROP, tractional retinal detachment and macular ectopia were not observed in any patients during follow-up. Conclusions: There was no difference in the short-term clinical outcomes of stage 3+ ROP in zone I or II between the eyes with low dose and conventional dose of IVB.

UR - http://www.scopus.com/inward/record.url?scp=84961786939&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84961786939&partnerID=8YFLogxK

U2 - 10.1111/aos.13004

DO - 10.1111/aos.13004

M3 - Article

C2 - 27011262

AN - SCOPUS:84961786939

VL - 96

SP - e475-e478

JO - Acta Ophthalmologica

JF - Acta Ophthalmologica

SN - 1755-375X

IS - 4

ER -